TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Percentage of Participants With Low Recovery LETE
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in Oxygenation criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Inflammatory/immunological biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Flexibility of IMCaL, IMCL and IHCL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in physical activity level
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: early postoperative problems
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Tolerated Dose (MTD) of BTCT4465A (Mosunetuzumab)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants with Complete Response as Assessed Using Standard Criteria for NHL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Inventory of Parent and Peer Attachment (IPPA)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: UCLA Loneliness Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Family Management Measure (FMM)
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Self-Perception Profile for Adolescents/Emerging Adults (SPPA/EA)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: NIH Toolbox - Friendship
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Total daily physical activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reduction in binge-drinking episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Varicella, MMR titres
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Eventration rate
Endpoint domain: Adverse events/effects
Primary endpoint: Urodynamic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change from baseline in the Age Equivalent Developmental score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Product safety defined by the incidence, type and severity of treatment-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of transfused units
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: BASFI (Bath Ankylosing Spodylitis Functionality Index)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Bronchial inflammation parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Variation among genes in siblings with cystic fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Necessity of mechanical ventilation and surfactant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Maintenance of Body Mass Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 24 weeks progression free survival
Endpoint domain: Mortality/survival
Primary endpoint: Patient experiences with acromegaly treatments
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient satisfaction with acromegaly treatments
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Health-related quality of life in patients with acromegaly
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Maximum serum concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Area under the serum cortisol concentration-time curve (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Area under the curve extrapolated to infinity (AUC0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Total Time Spent by Healthcare Professionals in Preparation/Administration of ERT
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acute radiation effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Moderate-late pulmonary and cardiac radiation effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Patients Reporting Symptomatic Hypoglycemic Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percent Change in Total Mean Clinical Target Volumes (CTV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peripheral Neuropathy assessed by sudoscan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cardiac Autonomic Neuropathy assessed by electrocardiogram (ECG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Adherence to Self-management
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Levels of procalcitonin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Levels of angiotensin II
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Total Hip Bone Mineral Density (BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delta AUC BG 0-2h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Dose-limiting toxic effects
Endpoint domain: Adverse events/effects
Primary endpoint: Tumor-to-background ratios (TBR)max and TBRmean thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in transition readiness score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Confirmed response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Sensitivity and specificity for imaging modalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remission on the Hamilton Rating Scale for Depression - 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive adverse effects as indexed by the Autobiographical Memory Test
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with a platelet response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Repeatability of the binocular OCY
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transfer Performance (TAI Scores Part 1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Sites Adherent to the Uterus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Severity Score of Sites Adherent to the Uterus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Extent Score of Sites Adherent to the Uterus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mTICI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Cerebral map activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Durability of local disease control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Subjects Reporting Solicited Adverse Events (AEs) After Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects Reporting Unsolicited AEs After Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects Reporting Unsolicited Serious Adverse Events (SAEs) After Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: HCV RNA suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: loss of reflex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CVLT-C Learning Slope
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: QoR-40
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of impairment of cerebral autoregulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: MRSA colonization prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Sensitivity and specificity of the diagnostic assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change From Baseline in Arm Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolution of diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in pulmonary artery pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of reclassification of CNVs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electroretinogram (ERG) - mixed cone-rod response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Electroretinogram (ERG) - cone flicker latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Depth of central venous catheter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Serum level of inflammatory and metabolic markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Agreement level on severity and extent of CD lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Nicotine Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to the Maximum Nicotine Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve From Start of Product Use (T0) to 4 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of successful dural puncture on the first needle insertion attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Event related electric amplitudes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of increasement of endoscopic detection of (pre)malignant gastric cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: 12-Month Progression Free Survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Freedom from atrial fibrillation/atrial tachycardia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants With Healthy Children Aged From 6 Months to <18 Years With Seroconversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Subjects Achieving Seroconversion for HI Antibody After Administration of the Study Vaccine Depending of the Number of Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroprotection Rate for HI Antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroprotection Rate of HI Antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clinical Interview for Depression and Related Syndromes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: visualization of cortical lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of Fluzoparib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve From 0 to t of Fluzoparib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve From 0 to infinity of Fluzoparib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve (AUC) from plasma concentrations of dabigatran
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective response (complete and partial)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Control of cardiovascular disease (CVD) risk factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Women's Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Efficacy of treatment for refractory cGVHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of PF 04965842
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCinf of PF 04965842
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: School performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Status Indicators for iron, zinc, vitamin A and iodine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Consumption of rescue analgesics
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of mild hypoglycaemic episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Efficacy of Chloroquine for P.vivax infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Plasma concentration of MPA and Premarin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PK parameters of MPA and Premarin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phytoestrogen absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Development of moderate to severe disease
Endpoint domain: Mortality/survival
Primary endpoint: Mean Change From Baseline in Corrected QT Intervals (QTcF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction of telomere attrition rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean of Perception of Anticoagulant Treatment Questionnaire 2 (PACT-Q2) Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Effectiveness of tracheal intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in severity of heartburn symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Prevalence of polymorphisms in candidate genes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of alleles in breast cancer patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relationships between candidate gene polymorphisms and hormone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Geometric Mean Fold Increase in SRH Antibody Titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Metabolomics-branched chain amino acids change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Insulin Sensitivity change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: calprotectine rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: 24 Hour Urinary Sodium Excretion Normalized to Creatinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Visual Analog Scale (VAS) improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Oral Intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportions of subjects reporting local reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Proportions of subjects reporting systemic events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportions of subjects reporting AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Proportions of subjects reporting SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Proportions of subjects with abnormal hematology and blood chemistry laboratory assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: CD4+ T-lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HIV Viral Load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: hsCRP (C-reactive protein)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fibrosis staging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post operative swelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Buccal Soft Tissue Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: MSK Ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Remission at 10 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remission maintained through to 24 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remission maintained through to 52 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of coronavirus infection
Endpoint domain: Adverse events/effects
Primary endpoint: Best Response at 4 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Michigan Diabetic Neuropathy Score (MDNS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Microbiological analysis of dentinal tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Patients With Donor Engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Modified Social Capital Scale (MSCS)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Poor control of asthma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Emotional deficit such as alexithymia
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Invasive respiratory effort
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of recording time spent with cuff overinflation or underinflation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aorto-related events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: change in power spectral density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in ischemic score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Increase in left ventricle ejection fraction (LVEF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in global hand pain assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Adjusted Symptom Score (AAdSS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pelvic Floor symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient self-reporting of daily function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Patient self-reported back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: very good partial response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance effects
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Endometrial Gene Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endometrial Maturation Using Noyes' Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Free Sulfide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bound Sulfide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acid Labile Sulfide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of Fentanyl
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Reach the Maximum Plasma Concentration (Tmax) of Fentanyl
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve From 0 to Last Quantifiable Concentration (AUC[0-last]) Post Dose of Fentanyl
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Death prior to discharge
Endpoint domain: Mortality/survival
Primary endpoint: Through-Focus High Contrast logMAR Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: B-CAM sensitivity and specificity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes